Major Depression With Psychotic Features
10
1
2
5
Key Insights
Highlights
Success Rate
63% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 54/100
30.0%
3 terminated out of 10 trials
62.5%
-24.0% vs benchmark
30%
3 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
EEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT
EPI-MINN: Targeting Cognition and Motivation - National
Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
Academic-Community EPINET (AC-EPINET)
Social Cognition in Longstanding Psychosis
Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis
Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis
Reducing Internalized Stigma in People With Serious Mental Illness
Treatment of Major Depressive Disorder With Psychotic Features.
Treatment of Depression With Quetiapine